Veracyte touts results of Decipher classifier study

By LabPulse.com staff writers

July 30, 2021 -- Veracyte announced new data from a study touting the success of its Decipher Prostate Biopsy genomic classifier in helping guide treatment decisions for prostate cancer patients who are candidates for active surveillance. Their findings were published July 20 in Prostate Cancer and Prostatic Diseases.

Researchers reviewed the Decipher risk scores from 855 men in the study to evaluate the independent association of Decipher high scores with the time to conversion from active surveillance to radical therapy and the time to treatment failure.

Of the 241 evaluable patients who elected to undergo active surveillance, a high-risk Decipher score was independently associated with shorter radical therapy. Men with high-risk scores spent significantly less time on active surveillance than men with Decipher low/intermediate risk scores (13.6 months versus 33 months), the company said.

Similarly, among the 479 evaluable patients who underwent definitive treatment either initially or after a period of active surveillance, those with a Decipher high-risk score had a significantly shorter time to treatment failure as compared to those with lower scores.

Veracyte taps new executive vice president, CFO
Global genomic diagnostics firm Veracyte has appointed Rebecca Chambers as its new executive vice president and chief financial officer (CFO). Her tenure...
Veracyte inks deal to purchase HalioDx
In a bid to expand its cancer diagnostics presence, Veracyte has signed an agreement to acquire immuno-oncology testing company HalioDx. The deal is expected...
Veracyte to highlight Decipher clinical data at ASCO
Veracyte plans to highlight results at the virtual American Society of Clinical Oncology (ASCO) from two studies that show its Decipher prostate genomic...
Veracyte completes Decipher acquisition for $600M
Veracyte has completed a $600 million cash deal to acquire Decipher Biosciences, expanding its position in the genomics-driven cancer diagnostics...
Veracyte to acquire Decipher Biosciences
Veracyte has announced plans to acquire Decipher Biosciences in a move that unites Veracyte's position in genomic cancer diagnostics with Decipher's activities...

Copyright © 2021 LabPulse.com

Last Updated ls 7/30/2021 10:06:08 AM